Dieter Zopf, Principal Scientist at Bayer AG, Research and Development, Pharmaceuticals, Oncology, discusses the clinical development of regorafenib (Stivarga) combinations in pediatric rhabdomyosarcoma.
Dieter Zopf
Advertisement
Articles by Dieter Zopf
Dieter Zopf, Principal Scientist at Bayer AG, Research and Development, Pharmaceuticals, Oncology, discusses the rationale for a study of regorafenib (Stivarga) combinations in pediatric patients with rhabdomyosarcomas (RMS).
Dieter Zopf, Principal Scientist at Bayer AG, Research and Development, Pharmaceuticals, Oncology, discusses the optimal partner for regorafenib (Stivarga) in pediatric rhabdomyosarcomas.
Dieter Zopf, Principal Scientist at Bayer AG, Research and Development, Pharmaceuticals, Oncology, discusses a study analyzing effective combinations with regorafenib for the treatment of pediatric rhabdomyosarcomas.
Advertisement
Latest Updated Articles
Identification of Combinations For Pediatric RhabdomyosarcomasOctober 22nd 2018
Optimal Regorafenib Combinations in Pediatric RhabdomyosarcomasNovember 1st 2018
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
3
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
4
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
5